Angina News and Research

RSS

Angina is chest pain or discomfort that occurs when an area of your heart muscle doesn't get enough oxygen-rich blood. Angina may feel like pressure or squeezing in your chest. The pain also may occur in your shoulders, arms, neck, jaw, or back. It can feel like indigestion.

Standard dose of UFH optimal for treatment of PCI patients on fondaparinux: Study

A landmark international study, coordinated by McMaster University, has found that lower doses of a blood thinner called unfractionated heparin (UFH) during angioplasty did not reduce bleeding or vascular complications compared to standard dose UFH in patients initially treated with a blood thinner, fondaparinux.

31 Aug 2010

$Unfractionated heparin standard dose may be optimal treatment strategy in PCI patients on fondaparinux$

Unfractionated heparin standard dose may be optimal treatment strategy in PCI patients on fondaparinux

Results from the FUTURA/OASIS 8 study presented today at the ESC Congress provide initial evidence that a low dose of unfractionated heparin does not reduce the incidence of bleeding or vascular complications in PCI patients treated with the anticoagulant fondaparinux. Findings showed that the rates of peri-PCI major bleeding were 1.4% in those given low dose heparin and 1.2% the standard dose.

31 Aug 2010

Phase 3 EINSTEIN-DVT clinical trial data can transform deep vein thrombosis treatment

Johnson & Johnson Pharmaceutical Research & Development, announced today that the investigational, oral anticoagulant rivaroxaban successfully demonstrated non-inferiority compared to the standard of care for the prevention of recurrent venous thromboembolism (VTE) in patients with acute symptomatic deep vein thrombosis (DVT), with a comparable safety profile.

31 Aug 2010

Data suggests BIMA improves coronary artery bypass graft efficiency

Recent trial data indicate that coronary artery bypass graft (CABG) surgery remains the most effective intervention for patients with severe coronary artery disease (CAD).

31 Aug 2010

J-LANCELOT trial finds E5555 may reduce MACE without increasing serious bleeding events

Aspirin and thienopyridine antiplatelet therapy (such as clopidogrel) are standard care in the treatment of acute coronary syndrome (ACS) and even in stable coronary artery disease (CAD) after coronary intervention with stent. However, effective antiplatelet agents are needed which do not increase the risk of bleeding.

31 Aug 2010

New research contradicts previous reports on blood-thinner clopidogrel

New findings by McMaster University researchers contradict earlier reports that people with a certain genetic make-up don't benefit from the blood-thinner clopidogrel, also known as Plavix.

30 Aug 2010

Study reveals impact of genetic make-up on response to oral antiplatelet treatment ticagrelor

A new genetic substudy of PLATO showed that the effects on a combined primary endpoint of cardiovascular death, myocardial infarction, or stroke seen in Acute Coronary Syndromes patients who received the investigational oral antiplatelet treatment, ticagrelor (BRILINTA), were maintained, whether or not they had the genetic variability that has been previously shown to affect a patient's response to clopidogrel.

30 Aug 2010

FDA approves Novartis' Tekamlo for treatment of high blood pressure

The US Food and Drug Administration (FDA) approved Tekamlo™ (aliskiren and amlodipine) tablets, a single-pill for the treatment of high blood pressure combining the only approved direct renin inhibitor, Tekturna® (aliskiren), with the widely used calcium channel blocker amlodipine. Tekamlo is approved as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals, and as replacement therapy for patients whose blood pressure is not adequately controlled with either aliskiren or amlodipine alone.

27 Aug 2010

Improvement of postoperative care decreases myocardial ischemia and major cardiac events

A study published in the October 2010 issue of Anesthesiology is among the first to show that the quality of immediate postoperative care of orthopedic surgery patients has important effects on patients' long-term cardiac outcomes.

25 Aug 2010

Sleep deprivation and chronic disease

Sleep experts believe that sleep deprivation and inadequate sleep is becoming frightfully common and it can be bad for health in more ways than one. According to Harvard School of Medicine's Healthy Sleep site there is a real link between chronic diseases like diabetes, heart disease and depression and chronic lack of sleep.

24 Aug 2010

Dilation of blood vessels restores muscle synthesis in elderly

University of Texas Medical Branch at Galveston researchers believe they've found a way to use widely available blood pressure drugs to fight the muscular weakness that normally accompanies aging.

21 Aug 2010

Neovasc revenue increases 60% for second quarter 2010

Neovasc Inc., today announced financial results for the three and six months ended June 30, 2010. "In this most recent quarter Neovasc continued to demonstrate robust year-over-year revenue growth from sales of our biological tissue and consulting services businesses," said Alexei Marko, chief executive officer of Neovasc.

19 Aug 2010

PLC Systems second-quarter total revenues decrease to $1,019,000

PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today reported financial results for the three- and six month periods ended June 30, 2010.

16 Aug 2010

Affymax, Takeda announce preliminary strategy for Hematide to treat anemia in chronic renal failure patients

Affymax, Inc. and Takeda Pharmaceutical Company Limited, today announced that the companies have decided on a preliminary strategic path forward for the investigational drug, Hematide™/peginesatide, for the treatment of anemia in chronic renal failure patients in the United States.

5 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Cardiogenesis second-quarter 2010 revenue increases 9% to $2.43 million

Cardiogenesis Corporation, a leading developer of surgical products used to treat cardiac patients suffering from severe angina, today reported financial results for its second quarter and first half ended June 30, 2010.

5 Aug 2010

Abnormal sleep duration adversely affects cardiovascular health

A study in the Aug. 1 issue of the journal Sleep suggests that regularly sleeping for more or less than seven hours per day is associated with an increased risk of cardiovascular disease.

2 Aug 2010

FDA Advisory Committee recommends approval of AstraZeneca's ticagrelor for Acute Coronary Syndromes

AstraZeneca today announced that the US Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee recommended the FDA approve AstraZeneca's investigational drug ticagrelor for the reduction of thrombotic events in patients with Acute Coronary Syndromes.

29 Jul 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

Gilead Sciences second-quarter total revenues increase 17% to $1.93 billion

Gilead Sciences, Inc. announced today its results of operations for the quarter ended June 30, 2010. Total revenues for the second quarter of 2010 were $1.93 billion, up 17 percent compared to total revenues of $1.65 billion for the second quarter of 2009. Net income for the second quarter of 2010 was $712.1 million, or $0.79 per diluted share, compared to net income for the second quarter of 2009 of $571.4 million, or $0.61 per diluted share.

21 Jul 2010

Angina News and Research

Further Reading

Standard dose of UFH optimal for treatment of PCI patients on fondaparinux: Study

Unfractionated heparin standard dose may be optimal treatment strategy in PCI patients on fondaparinux

Phase 3 EINSTEIN-DVT clinical trial data can transform deep vein thrombosis treatment

Data suggests BIMA improves coronary artery bypass graft efficiency

J-LANCELOT trial finds E5555 may reduce MACE without increasing serious bleeding events

New research contradicts previous reports on blood-thinner clopidogrel

Study reveals impact of genetic make-up on response to oral antiplatelet treatment ticagrelor

FDA approves Novartis' Tekamlo for treatment of high blood pressure

Improvement of postoperative care decreases myocardial ischemia and major cardiac events

Sleep deprivation and chronic disease

Dilation of blood vessels restores muscle synthesis in elderly

Neovasc revenue increases 60% for second quarter 2010

PLC Systems second-quarter total revenues decrease to $1,019,000

Affymax, Takeda announce preliminary strategy for Hematide to treat anemia in chronic renal failure patients

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Cardiogenesis second-quarter 2010 revenue increases 9% to $2.43 million

Abnormal sleep duration adversely affects cardiovascular health

FDA Advisory Committee recommends approval of AstraZeneca's ticagrelor for Acute Coronary Syndromes

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Gilead Sciences second-quarter total revenues increase 17% to $1.93 billion

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News